The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Are there promising treatment options for multiple myeloma on the horizon?
As high-risk patients with multiple myeloma (MM) continue to die from the disease, novel treatments are needed. In this interview, Irene Ghobrial, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses future options for therapy, aimed at improving the rate of survival. One treatment discussed was CAR T-cell therapy, particularly that directed against BCMA. Dr Ghobrial emphasizes that this treatment could “come in very strong” in the future and offers her opinions on the current treatment used for high-risk patients. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
